I began my career directly after my PhD by founding a chemical research laboratory (CRO) with my associate more than 20 years ago. A few years later, we developed an original synthesis route for methylene blue which we then have patented.
Today, I am Chairman and Chief Executive Officer of Provepharm Life Solutions, an independent, international pharmaceutical company based in France and the United States. Our mission is to innovate to develop the full potential of each molecule to provide treatments that help improve patients’ lives.
This third way, between biotechnology and generics, allows us to efficiently develop molecules (reducing risks and development costs while creating value) to make treatments more accessible. This is our responsibility as a pharmaceutical player. This challenge is more broadly part of a societal dimension for which I am convinced that every business leader has an important role to play. That’s why I have always naturally integrated a CSR perspective into our corporate activities, which allows us to ask ourselves the right questions, in terms of business of course, but also in terms of the impact on our ecosystem and on society at large.
Moreover, to accelerate our approach, we have set up an endowment fund involving the company’s various stakeholders. Its purpose is to support and conduct projects with a strong societal impact, particularly of a social, scientific, educational, and environmental nature, in order to enable economic and scientific development that respects both people and the environment.